What's Happening?
Science Corporation, founded by Max Hodak, is preparing to conduct its first human trials for a biohybrid brain-computer interface. The company aims to place a sensor on the surface of a human brain during scheduled surgeries, led by Yale neurosurgery
chair Murat Günel. The sensor, containing 520 electrodes, will record neural activity without penetrating brain tissue. Science Corp's long-term vision involves integrating lab-grown neurons with electronics to form a biological bridge between neural tissue and technology. The company has raised $230 million in Series C funding and plans to begin trials in 2027.
Why It's Important?
This development represents a significant step forward in brain-computer interface technology, potentially revolutionizing how neurological conditions are treated. By creating a biohybrid interface, Science Corp aims to enhance communication between the human brain and computers, offering new therapeutic possibilities and human enhancement. The approach could lead to more effective treatments for conditions like Parkinson's disease and provide early warnings for seizures. The integration of lab-grown neurons with electronics could outperform existing technologies, offering a more organic solution to brain-computer interaction.
